UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer

Annals of oncology, 2015-02, Vol.26 (2), p.354-362

2015

Volltextzugriff (PDF)

Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges

Current oncology (Toronto), 2018-10, Vol.25 (5), p.e373-384

2018

Volltextzugriff (PDF)

Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors

Current oncology (Toronto), 2014-12, Vol.21 (6), p.329-336

2014

Volltextzugriff (PDF)

Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020

Current oncology (Toronto), 2020-02, Vol.27 (1), p.52-60

2020

Volltextzugriff (PDF)

Diagnosis and management of congenital thrombophilia in the era of direct oral anticoagulants

Thrombosis research, 2020-01, Vol.185, p.72-77

2020

Volltextzugriff (PDF)

Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus

Current oncology (Toronto), 2018-10, Vol.25 (5), p.329-337

2018

Volltextzugriff (PDF)

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration

Annals of oncology, 2019-11, Vol.30 (11), p.1686-1688

2019

Volltextzugriff (PDF)

Canadian consensus: a new systemic treatment algorithm for advanced EGFR- mutated non-small-cell lung cancer

Current oncology (Toronto), 2020-04, Vol.27 (2), p.e146-155

2020

Volltextzugriff (PDF)

Factors influencing treatment selection and survival in advanced lung cancer

Current oncology (Toronto), 2017-04, Vol.24 (2), p.e115-122

2017

Volltextzugriff (PDF)

Consensus statement: summary of the Quebec Lung Cancer Network recommendations for prioritizing patients with thoracic cancers in the context of the COVID-19 pandemic

Current oncology (Toronto), 2020-06, Vol.27 (3), p.e313-317

2020

Volltextzugriff (PDF)

Phase II study of everolimus–erlotinib in previously treated patients with advanced non-small-cell lung cancer

Annals of oncology, 2014-02, Vol.25 (2), p.409-415

2014

Volltextzugriff (PDF)

Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer

Annals of oncology, 2017-10, Vol.28 (10), p.2481-2488

2017

Volltextzugriff (PDF)

A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol

Clinical lung cancer, 2024-09

2024

Volltextzugriff (PDF)

Trematodes coupled with neonicotinoids: effects on blood cell profiles of a model amphibian

Parasitology research (1987), 2021-06, Vol.120 (6), p.2135-2148

2021

Volltextzugriff (PDF)

A review of multistage membrane filtration approaches for enhanced efficiency during concentration and fractionation of milk and whey

International journal of dairy technology, 2022-11, Vol.75 (4), p.749-760

2022

Volltextzugriff (PDF)

Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer

Current oncology (Toronto), 2019-02, Vol.26 (1), p.e81-93

2019

Volltextzugriff (PDF)

Erratum: Therapeutic Landscape of Metastatic Non-Small-Cell Lung Cancer in Canada in 2020

Current oncology (Toronto), 2020-06, Vol.27 (3), p.349-349

2020

Volltextzugriff (PDF)

Standardizing biomarker testing for Canadian patients with advanced lung cancer

Current oncology (Toronto), 2018-02, Vol.25 (1), p.73-82

2018

Volltextzugriff (PDF)

Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort

ESMO open, 2024-05, Vol.9 (5), p.103004, Article 103004

2024

Volltextzugriff (PDF)

Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations

Current oncology (Toronto), 2015-02, Vol.22 (1), p.49-59

2015

Volltextzugriff (PDF)

Canadian perspectives: update on inhibition of ALK -positive tumours in advanced non-small-cell lung cancer

Current oncology (Toronto), 2018-10, Vol.25 (5), p.317-328

2018

Volltextzugriff (PDF)

2637 Baseline circulating tumor cells (CTC) and serum heat shock protein 27 (Hsp27) levels are increased in advanced bladder cancer (BC) patients with poor prognostic factors: Results from the randomized phase 2 Borealis-1™ trial of first-line gemcitabine/cisplatin plus apatorsen or placebo

European journal of cancer (1990), 2015-09, Vol.51, p.S525-S525

2015

Volltextzugriff (PDF)

Efficacité intracrânienne du sotorasib versus docétaxel dans le cancer bronchique non à petites cellules (CBNPC) métastatique muté KRAS G12C données utiles à la pratique issues d’un essai randomisé contrôlé

Revue des maladies respiratoires actualités, 2024-01, Vol.16 (1), p.265

2024

Volltextzugriff (PDF)

3091 Characterization of advanced NSCLC patients with prolonged benefit after veliparib plus carboplatin/paclitaxel: Phase 2 results

European journal of cancer (1990), 2015-09, Vol.51, p.S629-S630

2015

Volltextzugriff (PDF)

3093 Veliparib with carboplatin and paclitaxel: factors predictive of favorable outcomes in NSCLC

European journal of cancer (1990), 2015-09, Vol.51, p.S630-S630

2015

Volltextzugriff (PDF)

1 – 25 von 1.694

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.115)
Mit Volltextzugriff
(1.322)

Publikationsform

6 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(14)

Menü

Weitere Dienste

Einstellungen

A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer

Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges

Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors

Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020

Diagnosis and management of congenital thrombophilia in the era of direct oral anticoagulants

Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration

Canadian consensus: a new systemic treatment algorithm for advanced EGFR- mutated non-small-cell lung cancer

Factors influencing treatment selection and survival in advanced lung cancer

Consensus statement: summary of the Quebec Lung Cancer Network recommendations for prioritizing patients with thoracic cancers in the context of the COVID-19 pandemic

Phase II study of everolimus–erlotinib in previously treated patients with advanced non-small-cell lung cancer

Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer

A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol

Trematodes coupled with neonicotinoids: effects on blood cell profiles of a model amphibian

A review of multistage membrane filtration approaches for enhanced efficiency during concentration and fractionation of milk and whey

Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer

Erratum: Therapeutic Landscape of Metastatic Non-Small-Cell Lung Cancer in Canada in 2020

Standardizing biomarker testing for Canadian patients with advanced lung cancer

Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort

Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations

Canadian perspectives: update on inhibition of ALK -positive tumours in advanced non-small-cell lung cancer

2637 Baseline circulating tumor cells (CTC) and serum heat shock protein 27 (Hsp27) levels are increased in advanced bladder cancer (BC) patients with poor prognostic factors: Results from the randomized phase 2 Borealis-1™ trial of first-line gemcitabine/cisplatin plus apatorsen or placebo

Efficacité intracrânienne du sotorasib versus docétaxel dans le cancer bronchique non à petites cellules (CBNPC) métastatique muté KRAS G12C données utiles à la pratique issues d’un essai randomisé contrôlé

3091 Characterization of advanced NSCLC patients with prolonged benefit after veliparib plus carboplatin/paclitaxel: Phase 2 results

3093 Veliparib with carboplatin and paclitaxel: factors predictive of favorable outcomes in NSCLC

Suchergebnisse filtern